Literature DB >> 21930917

CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.

Renaud Le Floch1, Johanna Chiche, Ibtissam Marchiq, Tanesha Naiken, Tanesha Naïken, Karine Ilc, Karine Ilk, Clare M Murray, Susan E Critchlow, Danièle Roux, Marie-Pierre Simon, Jacques Pouysségur.   

Abstract

Malignant tumors exhibit increased dependence on glycolysis, resulting in abundant export of lactic acid, a hypothesized key step in tumorigenesis. Lactic acid is mainly transported by two H(+)/lactate symporters, MCT1/MCT4, that require the ancillary protein CD147/Basigin for their functionality. First, we showed that blocking MCT1/2 in Ras-transformed fibroblasts with AR-C155858 suppressed lactate export, glycolysis, and tumor growth, whereas ectopic expression of MCT4 in these cells conferred resistance to MCT1/2 inhibition and reestablished tumorigenicty. A mutant-derivative, deficient in respiration (res(-)) and exclusively relying on glycolysis for energy, displayed low tumorigenicity. These res(-) cells could develop resistance to MCT1/2 inhibition and became highly tumorigenic by reactivating their endogenous mct4 gene, highlighting that MCT4, the hypoxia-inducible and tumor-associated lactate/H(+) symporter, drives tumorigenicity. Second, in the human colon adenocarcinoma cell line (LS174T), we showed that combined silencing of MCT1/MCT4 via inducible shRNA, or silencing of CD147/Basigin alone, significantly reduced glycolytic flux and tumor growth. However, both silencing approaches, which reduced tumor growth, displayed a low level of CD147/Basigin, a multifunctional protumoral protein. To gain insight into CD147/Basigin function, we designed experiments, via zinc finger nuclease-mediated mct4 and basigin knockouts, to uncouple MCTs from Basigin expression. Inhibition of MCT1 in MCT4-null, Basigin(high) cells suppressed tumor growth. Conversely, in Basigin-null cells, in which MCT activity had been maintained, tumorigenicity was not affected. Collectively, these findings highlight that the major protumoral action of CD147/Basigin is to control the energetics of glycolytic tumors via MCT1/MCT4 activity and that blocking lactic acid export provides an efficient anticancer strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930917      PMCID: PMC3189052          DOI: 10.1073/pnas.1106123108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression.

Authors:  P Kirk; M C Wilson; C Heddle; M H Brown; A N Barclay; A P Halestrap
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

2.  A specific mutation abolishing Na+/H+ antiport activity in hamster fibroblasts precludes growth at neutral and acidic pH.

Authors:  J Pouysségur; C Sardet; A Franchi; G L'Allemain; S Paris
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

Review 3.  pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth.

Authors:  J Pouysségur; A Franchi; G Pagès
Journal:  Novartis Found Symp       Date:  2001

4.  Growth factor action and intracellular pH regulation in fibroblasts. Evidence for a major role of the Na+/H+ antiport.

Authors:  G L'Allemain; S Paris; J Pouysségur
Journal:  J Biol Chem       Date:  1984-05-10       Impact factor: 5.157

5.  Isolation of a Chinese hamster fibroblast mutant defective in hexose transport and aerobic glycolysis: its use to dissect the malignant phenotype.

Authors:  J Pouysségur; A Franchi; J C Salomon; P Silvestre
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

6.  A genetic approach to the role of energy metabolism in the growth of tumor cells: tumorigenicity of fibroblast mutants deficient either in glycolysis or in respiration.

Authors:  A Franchi; P Silvestre; J Pouysségur
Journal:  Int J Cancer       Date:  1981-06-15       Impact factor: 7.396

7.  The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells.

Authors:  K S Dimmer; B Friedrich; F Lang; J W Deitmer; S Bröer
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

8.  A null mutation in basigin, an immunoglobulin superfamily member, indicates its important roles in peri-implantation development and spermatogenesis.

Authors:  T Igakura; K Kadomatsu; T Kaname; H Muramatsu; Q W Fan; T Miyauchi; Y Toyama; N Kuno; S Yuasa; M Takahashi; T Senda; O Taguchi; K Yamamura; K Arimura; T Muramatsu
Journal:  Dev Biol       Date:  1998-02-15       Impact factor: 3.582

Review 9.  The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond.

Authors:  Andrew P Halestrap; David Meredith
Journal:  Pflugers Arch       Date:  2003-05-09       Impact factor: 3.657

10.  The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily.

Authors:  C Biswas; Y Zhang; R DeCastro; H Guo; T Nakamura; H Kataoka; K Nabeshima
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

View more
  178 in total

Review 1.  Role of monocarboxylate transporters in human cancers: state of the art.

Authors:  Céline Pinheiro; Adhemar Longatto-Filho; João Azevedo-Silva; Margarida Casal; Fernando C Schmitt; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 2.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 3.  Potential applications for biguanides in oncology.

Authors:  Michael Pollak
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

4.  In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.

Authors:  Xiaowen Guan; Marilyn E Morris
Journal:  AAPS J       Date:  2020-06-11       Impact factor: 4.009

Review 5.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.

Authors:  Xiaowen Guan; Mark A Bryniarski; Marilyn E Morris
Journal:  AAPS J       Date:  2018-11-05       Impact factor: 4.009

7.  Label-Free in Situ pH Monitoring in a Single Living Cell Using an Optical Nanoprobe.

Authors:  Qingbo Yang; Xiaobei Zhang; Yang Song; Ke Li; Honglan Shi; Hai Xiao; Yinfa Ma
Journal:  Med Devices Sens       Date:  2020-03-12

8.  Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Authors:  Joanne R Doherty; Chunying Yang; Kristen E N Scott; Michael D Cameron; Mohammad Fallahi; Weimin Li; Mark A Hall; Antonio L Amelio; Jitendra K Mishra; Fangzheng Li; Mariola Tortosa; Heide Marika Genau; Robert J Rounbehler; Yunqi Lu; Chi V Dang; K Ganesh Kumar; Andrew A Butler; Thomas D Bannister; Andrea T Hooper; Keziban Unsal-Kacmaz; William R Roush; John L Cleveland
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

9.  mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1.

Authors:  Joseph G Moloughney; Peter K Kim; Nicole M Vega-Cotto; Chang-Chih Wu; Sisi Zhang; Matthew Adlam; Thomas Lynch; Po-Chien Chou; Joshua D Rabinowitz; Guy Werlen; Estela Jacinto
Journal:  Mol Cell       Date:  2016-08-25       Impact factor: 17.970

10.  Hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane.

Authors:  Yi Rao; Seth Gammon; Niki M Zacharias; Tracy Liu; Travis Salzillo; Yuanxin Xi; Jing Wang; Pratip Bhattacharya; David Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.